OPKO Health, Inc. (NYSE: OPK) issued the following statement in response to inquiries about a report issued by Lakewood Capital Management challenging the potential of OPKO’s pipeline and business and investment initiatives:
We are aware of the report, which we believe is based on distorted and inaccurate information. We continue to believe in our unique business strategy and in the importance of OPKO’s therapeutic and diagnostic product candidates. We are fully committed to developing and commercializing our products and we look forward to updating investors in a timely manner.
OPKO will host an investor conference on Tuesday morning, December 17, 2013 in New York City. The presentation will also be available by webcast. Details for the presentation will be provided in a later release.
ABOUT OPKO HEALTH, INC.OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. For more information, visit http://www.opko.com. SAFE HARBOR STATEMENT This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding the potential for our therapeutic and diagnostic product candidates, as well as other non-historical statements about our expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as the risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments. In addition, forward-looking statements may also be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.